Alterity reports positive trial results
Alterity reports positive topline data from open-label phase II trial of ATH434 in multiple system atrophy
ATH434 demonstrated clinical benefit on Unified MSA Rating Scale and global measures of neurological symptoms
Neuroimaging biomarkers showed target engagement and slowed brain atrophy with drug well tolerated and having a favourable safety profile
The study, conducted in a patient population with more advanced disease than in the Alterity Therapeutics' (ASX:ATH) double-blind phase II trial, showed ATH434 was well tolerated and provided measurable clinical benefits, including stabilisation of neurological symptoms and slowed brain atrophy.
Over the 12-month treatment period, results indicated patients treated with ATH434 showed ~50% less disease progression on the Modified Unified MSA Rating Scale (UMSARS I) compared to historical controls.
Notably, 30% of participants reported stable or improved symptoms – an uncommon result in this advanced patient group.
In further encouraging results, 30% of participants also stabilised or improved on the Patient Global Impression of Change (PGIC) scale, which asks the patient to evaluate their overall neurological symptoms as compared to immediately before starting therapy.
ATH434 also helped stabilise symptoms of orthostatic hypotension, a common and serious drop in blood pressure when standing, in study participants.
Notably, the overall results suggest that ATH434 was just as effective in this more advanced group of MSA patients as it was in earlier-stage patients from the previous phase II double-blinded trial.
Neuroimaging data provided further support, showing a slowing of brain volume loss in MSA-affected regions and reduced iron accumulation – both consistent with the proposed mechanism of ATH434, which targets excess brain iron thought to drive MSA pathology.
Novel approach could provide much-needed therapy
Alterity's lead indication, MSA, is a rare and aggressive parkinsonian disorder with up to 50,000 patients in the US, driven by excess iron and aggregation of a protein called alpha-synuclein in the central nervous system.
ATH434 takes a novel approach to MSA by addressing iron imbalance and protein aggregation, offering what could be the first disease-modifying therapy.
The drug has been granted both fast track and orphan drug designations by the US Food and Drug Administration, as well as orphan drug status in the EU.
Backed by promising phase II and open-label phase II results, Alterity is chasing a market opportunity exceeding US$1.1 billion with ATH434.
About the open-label study
The phase II open label trial (ATH-434-202) was an open-label study in advanced MSA.
The trial enrolled participants diagnosed with MSA using a multimodal approach (clinical, neuroimaging, fluid biomarkers), who were treated with oral ATH434 75mg twice daily for 12 months.
The study assessed the safety and efficacy of ATH434 treatment on clinical and biomarker endpoints.
The pre-specified key clinical endpoints included the modified UMSARS I, the clinical global impression of change, and the patient global impression of change.
Enrolled participants were more advanced than those in the double-blind ATH434-201 phase II trial based on baseline variables including duration of motor symptoms, UMSARS I score, frequency of severe orthostatic hypotension, and plasma NFL levels.
Based on the observed clinical and neuroimaging data, ATH434 improved overall neurological symptoms and slowed disease progression compared to historical data.
'Strongly support advancing our ATH434 program'
CEO Dr David Stamler said he was very encouraged by the positive results from the ATH434-202 trial, as they reinforce the robust efficacy we observed in its phase II study.
'The data from our phase II studies are consistent and strongly support advancing our ATH434 program in MSA,' he said.
'With the favourable clinical and biomarker outcomes we have seen, we continue to believe that ATH434 has the potential to slow the progression of this devastating disease.
'We are committed to bringing this new therapy to patients as soon as possible.'
The trial's lead investigator, professor Daniel Claassen from Vanderbilt University Medical Centre said the results were very helpful in establishing the clinical response to therapy.
He said the consistent changes in UMSARS, along with quantitative measures in imaging, support the findings noted in the phase II trial.
'Currently, there are no disease modifying medications for the treatment of MSA, and these data encourage the continued development of ATH434 to treat this disease,' he said.
'We are indebted to the study participants and their families who contributed to this study.'
This article was developed in collaboration with Alterity Therapeutics, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
a few seconds ago
- ABC News
TikTok and online games driving surge in Defence Force recruitment
Targeted advertising on social media and in online games has helped deliver a boost to Australian Defence Force recruitment, offsetting a perennial problem of declining service rates. Figures from the federal government show the permanent and full-time headcount reached more than 61,000 personnel, reflecting an annual increase of almost 1,900 people, the highest in 15 years. Year-on-year, it reflects a 17 per cent increase in the number of people joining the ADF, which Defence Personnel Minister Matt Keogh attributed to "smarter" career advertising. "So, doing that advertising in games, in computer games, utilising TikTok," he said. "Making sure that we're focusing on having that advertising presented where our target age groups are, so they are seeing those messages and they're seeing the breadth of role types that are available across the Australian Defence Force." Fewer than 10 per cent of the more than 75,000 people who applied ultimately enlisted in the ADF. Of the more than 7,000 people who joined the ADF, around half were in the Army (3,442). This took its headcount to a four-year high. Enlistment in the Navy (1,524) and Air Force (2,093) saw their respective overall headcounts reach their highest levels since 2006. Mr Keogh partially attributed a broadening of entry eligibility for a five-year high in applications. "We had a situation before where medical conditions like acne could automatically exclude someone from being able to enlist," he said. "Clearly that's stupid in the 21st century. "We're now making sure that our eligibility requirements match the more than 300 different types of roles that are available in the Defence Force. "So, if you're doing something like cyber ops, you know, you're working out of a basement, you're never leaving Australia, we don't need to have as strict requirements as might be required as someone who's going to be in an infantry force that's going to be deployable outside of Australia." The median age of recruits was 23 years. Mr Keogh and ADF chief of personnel Natasha Fox said responding to the Veterans' Suicide Royal Commission had also helped bolster people's willingness to join the military. Defence has long struggled to recruit and retain personnel, in part due to accusations about the culture within the ADF. So, the government has also trumpeted a decline in the rate of people leaving the ADF, down from 11.2 per cent in 2021/22 to 7.9 per cent — the lowest rate in a decade. Figures released last year showed the ADF had a shortfall of around 4,400 workers. It remains unclear to what extent that has been reduced in the past year's intake. But officials have insisted the government was on track to reach its target of 69,000 permanent workers by the early 2030s. "We're also conscious that we have more work to do in this area as well," Mr Keogh said. A year ago, the government announced foreign nationals would be able to serve in the ADF in a bid to boost recruitment. Initially starting with New Zealanders, Australian permanent residents from the UK, US and Canada (members of the so-called Five Eyes intelligence sharing network) are now eligible to apply to join the ADF. But so far, only three New Zealanders have enlisted. Figures from the government show a further 70 people are in a pre-enlistment phase, and are expected to officially join in the coming months. As of July 13, there were 520 active applications from Five Eyes citizens, of which 400 were from New Zealand. The United Kingdom had the second most applicants, followed by the United States and Canada.
The Australian
17 minutes ago
- The Australian
Australia commits $20m in humanitarian aid in Gaza
Australia will commit a further $20m to assist the delivery of critical food and aid to starving Gazans, as health authorities confirmed reporting that 163 people had died of starvation, including 93 children. The move comes amid growing international pressure for Australia to join the UK, France and Canada in committing to recognising Palestinian statehood at the United Nations General Assembly in September, which will be attended by Anthony Albanese. Foreign Minister Penny Wong confirmed the additional $20m aid package on Sunday night, which brings Australia's total contribution to $130m. The assistance will be delivered through key partners and humanitarian organisations will be broken into five different components. The announcement comes after the Israeli government relented to the establishment of humanitarian corridors, following intense global condemnation it was purposefully starving civilians in Gaza – claims Israeli Prime Minister Israeli Netanyahu have denied and labelled a 'bold-faced lie'. $2m has been earmarked for relief support alongside the UK though the existing partnership arrangement, $6m will be spent through the UN World Food Programme for the distribution for critical food supplies. The government's $20m commitment comes as huge pro-Palestine rallies hit Sydney and Melbourne on Sunday. Picture: NewsWire / Brendan Read $5m have also been committed both to UNICEF to target children at risk of starvation, as well as the International Committee of the Red Cross to provide essential needs, like healthcare. Another $2m will be delivered through the Jordan Hashemite Charity Organisation to bolster the operations of field hospitals in the war zone. Senator Wong reiterated her demands of a ceasefire, with the US and Israel restarting negotiations for a peace deal. The move also comes after more than 50,000 anti-war protesters shut down Sydney Harbour Bridge on Sunday, demanding more action, with similar large-scale demonstrations happening in Melbourne's CBD. 'Australia has consistently been part of the international call on Israel to allow a full and immediate resumption of aid to Gaza, in line with the binding orders of the International Court of Justice,' she said. 'The suffering and starvation of civilians in Gaza must end. 'Australia will continue to work with the international community to call for an immediate and permanent ceasefire, the release of hostages and a two-state solution – the only path to enduring peace and security for the Israeli and Palestinian peoples.' Foreign Minister Penny Wong reiterated calls for a ceasefire and said the 'suffering and starvation of civilians in Gaza must end'. Picture: NewsWire/ Martin Ollman International Development Minister Dr Anne Aly said the government was working with partners to provide the 'immediate and sustained lifesaving assistance' and urged the Israeli government to allow teams to 'do their vital work and deliver aid at scale'. 'Australia's additional funding will bolster international efforts to address urgent needs in Gaza. It will provide urgently needed food and healthcare,' she said. 'We continue to call on Israel to allow immediate and unimpeded aid access into Gaza.' The announcements come as Anthony Albanese seeks a call with Mr Netanyahu, following sustained speculation around whether Australia will join its Western Allies in recognising Palestinian statehood at the international summit next month. Mr Albanese has repeatedly said the act cannot just be a 'gesture' but must go towards achieving a two-state solution and peace in Gaza. The Coalition has said peace needs to be resolved before they support the recognition of statehood, which would require Hamas to surrender and release the Israeli hostages taken during the October 7 attacks. Jessica Wang NewsWire Federal Politics Reporter Jessica Wang is a federal politics reporter for NewsWire based in the Canberra Press Gallery. She previously covered NSW state politics for the Wire and has also worked at and Mamamia covering breaking news, entertainment, and lifestyle. @imjesswang_ Jessica Wang
News.com.au
3 hours ago
- News.com.au
Are thermal receipts actually toxic?
Welcome to Ask Doctor Zac, a weekly column from This week, Dr Zac Turner explores whether or not thermal receipts are toxic. QUESTION: Hi Dr Zac, I recently saw a viral video claiming the ATO is 'killing us softly' through thermal receipts – apparently they're coated in BPA and other hormone-disrupting chemicals. As someone who handles receipts at work all day (shoutout to retail life), I'm now kind of freaked out. Should we be worried about the long-term effects of touching them, or is this another TikTok conspiracy? – Jodie, 34, Wollongong NSW ANSWER: Hi Jodie, Good news – for once, TikTok has stumbled onto some real science. Thermal receipts – those shiny ones that fade faster than a politician's promise – often contain Bisphenol A (BPA) or its chemical sibling, BPS. These compounds are used in thermal printing to create text without ink. But here's the rub: both are known endocrine disrupters, meaning they can interfere with your hormones, especially oestrogen (National Health and Medical Research Council, 2020). What's more worrying is that BPA can be absorbed through the skin. A 2014 study in Environmental Health Perspectives found that people who handled receipts frequently – particularly with moisturised or greasy hands – absorbed measurable amounts of BPA. Another Australian study confirmed that regular skin contact can lead to significant exposure. Now, don't panic and start wrapping your hands in cling wrap. Most of the alarming research involves high-dose exposure, usually in industrial settings or lab environments. But for retail and hospitality workers handling receipts every day, the cumulative effect is something to take seriously. So how can you protect yourself without quitting your job or demanding a full PPE kit? 1. Wash your hands – and skip the wipes Regular soap and water is more effective than antibacterial wipes when it comes to removing BPA residue. Easy, quick, and no need to buy anything fancy. 2. Keep your hands away from your face BPA doesn't need an invitation to hop from your fingertips to your mouth or eyes. Less contact, less risk. 3. Wear gloves if you're pregnant or working full-time with receipts Especially in busy environments where they're flying out like confetti. Disposable gloves can make a real difference — and no, they don't make you look ridiculous. 4. Go digital If you're the customer, skip the paper. Most retailers now offer email or text receipts. It's cleaner, safer, and you'll stop collecting receipts for things you returned two months ago. 5. Don't be fooled by 'BPA-free' Many retailers have switched to BPS-coated paper instead. But early research suggests BPS may be just as hormonally active – possibly worse in some cases. So it's a bit like replacing cigarettes with cigars and calling it progress. Ultimately, we need broader changes – better regulation and safer materials. France banned BPA receipts in 2019. Australia's not there yet, but retail workers like you raising concerns is how change starts. So yes, Jodie, your instincts were right. This isn't conspiracy – it's chemistry. And when it comes to protecting your hormones, even small changes count. Stay sharp, Dr Zac Dr Zac Turner is a medical practitioner specialising in preventative health and wellness. He has four health/medical degrees – Bachelor of Medicine/Bachelor of Surgery at the University of Sydney, Bachelor of Nursing at Central Queensland University, and Bachelor of Biomedical Science at the University of the Sunshine Coast. He is a registrar for the Australian College of Rural and Remote Medicine, and is completing a PhD in Biomedical Engineering (UNSW). Dr Zac is the medical director for his own holistic wellness medical clinics throughout Australia, Concierge Doctors.
